Palmoplantar Keratoderma (PPK) Market by Region (United States, Japan, U.K. Spain, Italy, France, Germany, and Mexico) and – Global Analysis of Market Size, Share & Trends for 2019–2020 and Forecasts to 2030

$5,000$10,000

Global Palmoplantar Keratoderma (PPK) Market is expected to project a notable CAGR of 2.87% in 2030.

Clear

Description

Palmoplantar Keratoderma (PPK) Market by Region (United States, Japan, U.K. Spain, Italy, France, Germany, and Mexico) and – Global Analysis of Market Size, Share & Trends for 2019–2020 and Forecasts to 2030
[175+ Pages Research Report] Global Palmoplantar Keratoderma (PPK) Market to reach USD 1,458.8 Million by 2030 from USD 1,098.9 Million in 2020 at a CAGR of 2.87% in the coming years, i.e., 2021-30.

Product Overview

Palmoplantar keratodermas (PPK) is a group of illnesses characterized by the thickening of the skin on the palms and soles of affected individuals’ feet. PPK can be classified into different categories such as hereditary forms with only skin complications, hereditary syndromes with PPK as an associated feature, and acquired forms. Hereditary PPK is the most common form of PPK which is generally diagnosed in the affected patients. Hereditary forms can be limited to the hands and feet, or they might be linked to a more widespread skin condition. Genetic mutations produce inherited PPKs, which result in keratin (a skin protein) abnormalities. Autosomal dominant or autosomal recessive inheritance can occur depending on the genetic reason. Acquired PPKs, on the other hand, might occur as a result of changes in a person’s health or surroundings.

Market Highlights

Global Palmoplantar Keratoderma (PPK) Market is expected to project a notable CAGR of 2.87% in 2030.
Global Palmoplantar Keratoderma (PPK) Market is anticipated to witness lucrative growth opportunities in the coming years. Rising prevalence of PPK across the 7MM has triggered health concerns among the economies. Governments across the 7MM are increasing funding and grants for research and development activities for the production & invention of new medicines to develop new therapies which is proliferating the growth of the PPK market.

Market Dynamics

Drivers

Persistent research & development towards understanding the pathophysiology Across the globe organizations are consistently working towards understanding the pathophysiology of Palmoplantar Keratoderma (PPK). Few clinical trials initiated for the treatment of Palmoplantar Keratoderma namely; SGT-210 (Sol-Gel) and others. Sol-Gel is a dermatology company that is investigating its product SGT-210. It is the epidermal growth factor receptor (EGFR) inhibitor, which is administered topically. For Instance, EGFR induces cell differentiation and proliferation upon activation through the binding of one of its ligands. This product is targeting patients with punctate palmoplantar keratoderma type -1 (PPPK type 1).

Restraint

Stringent rules & regulations
Governments across the 7MM have implemented numerous stringent rules and regulations relating to the clinical trial for the drugs of PPK, which are significantly hampering the PPK market in the 7MM. For instance, there is potential adverse federal, state and local government regulation in the United States.
Global Palmoplantar Keratoderma (PPK) Market: Key Players
 Cilas, Murata Manufacturing Co.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
 Ltd., Ceranova Corporation
 Brightcrystals Technology Inc.
 Ceramtec-Etec GmbH
 Coorstek, Inc.
 Konoshima Chemicals Co.Ltd.
 Surmet Corporation
 Schott AG
 II-VI Optical Systems
 Advanced Ceramic Manufacturing
 LLC
 Other Prominent Players
Global Palmoplantar Keratoderma (PPK) Market: Regions
Global Palmoplantar Keratoderma (PPK) Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific and the Middle East and Africa.
As per our estimates, In the United States, the availability of coverage and adequate reimbursement from third-party payors is a factor in the sale of any product that have received regulatory approval for commercial sale. Government agencies and health programs, such as Medicare and Medicaid, as well as managed care providers, private health insurers, and other organizations, are examples of third-party payors. Pricing and reimbursement schemes in the EU vary significantly from nation to nation. Some governments stipulate that the companies can only sell their products if a reimbursement price has been agreed upon. Additional research comparing the cost-effectiveness of a given product to already available therapies is might be required in some regions.

Additional information

Publisher

Geography Covered

Date Published

,

Pages

Format

Table of Contents

Contents
1. Report Introduction
1. Introduction
1. Scope of Study
2. Executive Summary
3. SWOT Analysis
1. Overview
4. Disease Background and Overview
1. Introduction
1. Diffuse Hereditary PPK:
2. Focal and Striate Hereditary PPK
3. Punctate Hereditary PPK
2. Causes
3. Pathophysiology
4. Risks and Symptoms
5. Diagnosis
5. Country-Specific Patient Population of Palmoplantar Keratoderma
1. United States
6. Mexico
1. Europe
2. Asia-Pacific
7. Japan
1. Current Treatment and Medical Practices
8. Patients Journey
9. Unmet Needs
1. Overview
10. Palmoplantar Keratoderma: Market Size Analysis
11. Country-Wise Market Analysis
1. United States
2. Mexico
3. Germany
4. France
5. Italy
6. Spain
7. United Kingdom
8. Japan
12. Market Access and Reimbursement of PPK
1. Overview
1. United States
2. Europe
3. Japan
13. Market Barriers
1. Overview
1. Scarcity of clinical trials and absence of information
2. Stringent rules & regulations
3. High cost involved in research and development
14. Market Drivers
1. Overview
1. Persistent research & development towards understanding the pathophysiology
2. Increasing investments in healthcare infrastructural development
3. Rise in prevalent cases of chronic patients
4. Government initiatives
15. Attribute Analysis
1. Overview
16. Appendix
1. List of Abbreviations
17. Research Methodology
1. Research Objective
2. Research Approach
3. Data Sourcing and Methodology
4. Secondary Research
5. Market Size Estimation and Data Triangulation
18. Disclaimer

RSS
Follow by Email